Decitabine and Vorinostat Cooperate To Sensitize Colon Carcinoma Cells to Fas Ligand-Induced Apoptosis In Vitro and Tumor Suppression In Vivo

The death receptor Fas and its physiological ligand (FasL) regulate apoptosis of cancerous cells, thereby functioning as a critical component of the host cancer immunosurveillance system. To evade Fas-mediated apoptosis, cancer cells often downregulate Fas to acquire an apoptosis-resistant phenotype, which is a hallmark of metastatic human colorectal cancer. Therefore, targeting Fas resistance is of critical importance in Fas-based cancer therapy and immunotherapy. In this study, we demonstrated that epigenetic inhibitors decitabine and vorinostat cooperate to upregulate Fas expression in metastatic human colon carcinoma cells. Decitabine also upregulates BNIP3 and Bik expression, whereas vorinostat decreased Bcl-xL expression. Altered expression of Fas, BNIP3, Bik, and Bcl-xL resulted in effective sensitization of the metastatic human colon carcinoma cells to FasL-induced apoptosis. Using an experimental metastasis mouse model, we further demonstrated that decitabine and vorinostat cooperate to suppress colon carcinoma metastasis. Analysis of tumor-bearing lung tissues revealed that a large portion of tumor-infiltrating CD8+ T cells are FasL+, and decitabine and vorinostat-mediated tumor-suppression efficacy was significantly decreased in Fasgld mice compared with wild-type mice, suggesting a critical role for FasL in decitabine and vorinostat-mediated tumor suppression in vivo. Consistent with their function in apoptosis sensitization, decitabine and vorinostat significantly increased the efficacy of CTL adoptive transfer immunotherapy in an experimental metastasis mouse model. Thus, our data suggest that combined modalities of chemotherapy to sensitize the tumor cell to Fas-mediated apoptosis and CTL immunotherapy is an effective approach for the suppression of colon cancer metastasis.

[1]  E. Borden,et al.  Combinations of DNA Methyltransferase and Histone Deacetylase Inhibitors Induce DNA Damage in Small Cell Lung Cancer Cells: Correlation of Resistance with IFN-Stimulated Gene Expression , 2010, Molecular Cancer Therapeutics.

[2]  P. Fisher,et al.  Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway. , 2010, Cancer research.

[3]  W. Tan,et al.  Functional Variants in Cell Death Pathway Genes and Risk of Pancreatic Cancer , 2008, Clinical Cancer Research.

[4]  Jamie L. Harden,et al.  Central Role of Tumor-Associated CD8+ T Effector/Memory Cells in Restoring Systemic Antitumor Immunity1 , 2009, The Journal of Immunology.

[5]  S. H. Lee,et al.  Somatic mutations in the death domain of the Fas (Apo-1/CD95) gene in gastric cancer. , 2001, The Journal of pathology.

[6]  N. Jenkins,et al.  Generalized lymphoproliferative disease in mice, caused by a point mutation in the fas ligand , 1994, Cell.

[7]  A. Marx,et al.  The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. , 2001, Blood.

[8]  S. Nagata,et al.  Apoptosis by Death Factor , 1997, Cell.

[9]  John D. Roberts,et al.  Vorinostat and Sorafenib Synergistically Kill Tumor Cells via FLIP Suppression and CD95 Activation , 2008, Clinical Cancer Research.

[10]  K. Robertson,et al.  Verticillin A overcomes apoptosis resistance in human colon carcinoma through DNA methylation-dependent upregulation of BNIP3. , 2011, Cancer research.

[11]  B. Fox,et al.  Disruption of TGF-β Signaling Prevents the Generation of Tumor-Sensitized Regulatory T Cells and Facilitates Therapeutic Antitumor Immunity1 , 2009, The Journal of Immunology.

[12]  P. Krammer,et al.  Cutting Edge: In Contrast to Effector T Cells, CD4+CD25+FoxP3+ Regulatory T Cells Are Highly Susceptible to CD95 Ligand- but Not to TCR-Mediated Cell Death1 , 2005, The Journal of Immunology.

[13]  R. Weissleder,et al.  Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-β signals in vivo , 2005 .

[14]  R. Siegel,et al.  The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity , 2000, Nature Immunology.

[15]  L. Berczi,et al.  Hypermethylation of the gene promoter and enhancer region can regulate Fas expression and sensitivity in colon carcinoma , 2003, Cell Death and Differentiation.

[16]  Xiaoling Hu,et al.  TNFα Cooperates with IFN-γ to Repress Bcl-xL Expression to Sensitize Metastatic Colon Carcinoma Cells to TRAIL-mediated Apoptosis , 2011, PLoS ONE.

[17]  Lauren P. Virtuoso,et al.  Activated CD8+ T-Effector/Memory Cells Eliminate CD4+ CD25+ Foxp3+ T-Suppressor Cells from Tumors via FasL Mediated Apoptosis1 , 2009, The Journal of Immunology.

[18]  S. Nagata,et al.  Lethal effect of the anti-Fas antibody in mice , 1993, Nature.

[19]  B. Beutler,et al.  Antigen-Specific Cytotoxicity by Invariant NKT Cells In Vivo Is CD95/CD178-Dependent and Is Correlated with Antigenic Potency , 2010, The Journal of Immunology.

[20]  J. Holland,et al.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Shuang Huang,et al.  DNA Methylation Represses IFN-γ–Induced and Signal Transducer and Activator of Transcription 1–Mediated IFN Regulatory Factor 8 Activation in Colon Carcinoma Cells , 2008, Molecular Cancer Research.

[22]  T. Lehnert,et al.  Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease , 2005, Gut.

[23]  F. Rieux-Laucat,et al.  A survey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutation. , 2011, Blood.

[24]  D. Israeli,et al.  p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs , 1998, The Journal of experimental medicine.

[25]  B. Camoretti-Mercado,et al.  Fas Resistance of Leukemic Eosinophils Is Due to Activation of NF-κB by Fas Ligation1 , 2002, The Journal of Immunology.

[26]  A. Snow,et al.  Resistance to Fas-Mediated Apoptosis in EBV-Infected B Cell Lymphomas Is Due to Defects in the Proximal Fas Signaling Pathway1 , 2001, The Journal of Immunology.

[27]  A. Bielawska,et al.  IRF8 regulates acid ceramidase expression to mediate apoptosis and suppresses myelogeneous leukemia. , 2011, Cancer research.

[28]  M. H. Ryan,et al.  The Fas/Fas Ligand Pathway Is Important for Optimal Tumor Regression in a Mouse Model of CTL Adoptive Immunotherapy of Experimental CMS4 Lung Metastases , 2003, The Journal of Immunology.

[29]  S. Ramalingam,et al.  Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  B. Camoretti-Mercado,et al.  Fas resistance of leukemic eosinophils is due to activation of NF-kappa B by Fas ligation. , 2002, Journal of immunology.

[31]  Ya‐Wen Cheng,et al.  A Polymorphic −844T/C in FasL Promoter Predicts Survival and Relapse in Non–Small Cell Lung Cancer , 2011, Clinical Cancer Research.

[32]  A. Strasser,et al.  Activation of Fas by FasL induces apoptosis by a mechanism that cannot be blocked by Bcl-2 or Bcl-x(L). , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Alexandra G. Smith,et al.  Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. , 2003, Cancer research.

[34]  Q. Wei,et al.  FAS and FASLG Genetic Variants and Risk for Second Primary Malignancy in Patients with Squamous Cell Carcinoma of the Head and Neck , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[35]  P. Krammer,et al.  In contrast to effector T cells, CD4+CD25+FoxP3+ regulatory T cells are highly susceptible to CD95 ligand- but not to TCR-mediated cell death. , 2005, Journal of immunology.

[36]  J. Houghton,et al.  The fas signaling pathway is functional in colon carcinoma cells and induces apoptosis. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  J. B. Oliveira,et al.  Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome. , 2010, Blood.

[38]  K. Koretz,et al.  Expression of APO‐1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium , 1994, International journal of cancer.

[39]  Ethan M. Shevach,et al.  CD4+CD25+ suppressor T cells: more questions than answers , 2002, Nature Reviews Immunology.

[40]  R. Siegel,et al.  Systemic autoimmunity and defective Fas ligand secretion in the absence of the Wiskott-Aldrich syndrome protein. , 2010, Blood.

[41]  B. Leyland-Jones,et al.  Azacitidine: 10 years later. , 1987, Cancer treatment reports.

[42]  H Hengartner,et al.  Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. , 1994, Science.

[43]  N. McCarthy.  Epigenetics: Worth another look? , 2011, Nature Reviews Cancer.

[44]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[45]  A. Leonardi,et al.  NF-κB-dependent cytokine secretion controls Fas expression on chemotherapy-induced premature senescent tumor cells , 2011, Oncogene.

[46]  T. Sayers,et al.  Tumor-Specific CTL Kill Murine Renal Cancer Cells Using Both Perforin and Fas Ligand-Mediated Lysis In Vitro, But Cause Tumor Regression In Vivo in the Absence of Perforin1 , 2002, The Journal of Immunology.

[47]  P. Fisher,et al.  Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation , 2008, Cancer biology & therapy.

[48]  E. Van Cutsem,et al.  Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer , 2008, Investigational New Drugs.

[49]  O. Surova,et al.  Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL. , 2011, Carcinogenesis.

[50]  Dafeng Yang,et al.  Downregulation of IFN‐γR in association with loss of Fas function is linked to tumor progression , 2008, International journal of cancer.

[51]  V. Seshan,et al.  HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. , 2011, Blood.

[52]  P. Fisher,et al.  Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95 , 2008, Molecular Cancer Therapeutics.

[53]  R. Hills,et al.  A functional variant in the core promoter of the CD95 cell death receptor gene predicts prognosis in acute promyelocytic leukemia. , 2012, Blood.

[54]  P. Krammer.  CD95(APO-1/Fas)-mediated apoptosis: live and let die. , 1999, Advances in immunology.

[55]  Boguslaw Stec,et al.  The Fas/FADD death domain complex structure unravels signaling by receptor clustering , 2008, Nature.

[56]  Dafeng Yang,et al.  CTL Adoptive Immunotherapy Concurrently Mediates Tumor Regression and Tumor Escape , 2006, The Journal of Immunology.

[57]  G. Rosner,et al.  Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy , 2011, Cancer.

[58]  R. Weissleder,et al.  Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[59]  Xiaoling Hu,et al.  IFN-γ Upregulates Survivin and Ifi202 Expression to Induce Survival and Proliferation of Tumor-Specific T Cells , 2010, PloS one.

[60]  Ralph Weissleder,et al.  Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation. , 2006, Immunity.

[61]  J. B. Oliveira,et al.  ALPS-ten lessons from an international workshop on a genetic disease of apoptosis. , 2010, Immunity.

[62]  M. Rivas,et al.  Immunization with Murine Breast Cancer Cells Treated with Antisense Oligodeoxynucleotides to Type I Insulin-Like Growth Factor Receptor Induced an Antitumoral Effect Mediated by a CD8+ Response Involving Fas/Fas Ligand Cytotoxic Pathway1 , 2006, The Journal of Immunology.

[63]  M. Sporn,et al.  Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. , 2011, The Journal of clinical investigation.

[64]  L. Owen-Schaub,et al.  Fas and Fas Ligand Interactions Suppress Melanoma Lung Metastasis , 1998, The Journal of experimental medicine.

[65]  M. Todaro,et al.  Vγ9Vδ2 T Lymphocytes Efficiently Recognize and Kill Zoledronate-Sensitized, Imatinib-Sensitive, and Imatinib-Resistant Chronic Myelogenous Leukemia Cells , 2010, The Journal of Immunology.

[66]  M. Zheng,et al.  FAS −1,377 G/A polymorphism is associated with cancer susceptibility: evidence from 10,564 cases and 12,075 controls , 2009, Human Genetics.

[67]  K. Schulze-Osthoff,et al.  The DNA methyltransferase inhibitors zebularine and decitabine induce mitochondria‐mediated apoptosis and DNA damage in p53 mutant leukemic T cells , 2012, International journal of cancer.

[68]  R. Lotan,et al.  Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells , 2007, Molecular Cancer Therapeutics.

[69]  R. Offringa,et al.  Immune Escape of Tumors in Vivo by Expression of Cellular Flice-Inhibitory Protein , 1999, The Journal of experimental medicine.

[70]  Gemma K. Alderton.  Microenvironment: Protective surroundings , 2011, Nature Reviews Cancer.

[71]  R. Arceci.  Antitumor Effects of a Combined 5-Aza-2′Deoxycytidine and Valproic Acid Treatment on Rhabdomyosarcoma and Medulloblastoma in Ptch Mutant Mice , 2009 .